Latest Financial Results

2018

Year End Results

Ended Oct 31, 2018

Stock Information

Symbol

ANIX

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

By using the body's immune system, Anixa Biosciences is taking multiple approaches to fighting cancer-developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. Anixa is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Anixa is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.

Logo Itus

Latest News & Events

Anixa Biosciences to Hold Conference Call to Discuss Outlook for 2019

Read More...

Anixa Biosciences Announces Completion of Pre-Sub Meeting with FDA for its Cchek™ Cancer Diagnostic Test

Read More...

Anixa Biosciences Presents Positive Data on its Liquid Biopsy for Early Detection of Breast Cancer at AACR Conference

Read More...

Cancer Fact: Approximately 40 million mammograms are conducted annually.